Literature DB >> 3697857

Withdrawal of oxyphenbutazone: what about phenylbutazone?

P Biron.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3697857      PMCID： PMC1491052     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  7 in total

1.  Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone.

Authors:  W H Inman
Journal:  Br Med J       Date:  1977-06-11

2.  Rare toxicity with nonsteroidal antiinflammatory drugs.

Authors:  G R Kraag
Journal:  J Rheumatol       Date:  1985-02       Impact factor: 4.666

3.  Rare adverse reactions to nonsteroidal antiinflammatory drugs.

Authors:  W M O'Brien; G F Bagby
Journal:  J Rheumatol       Date:  1985-02       Impact factor: 4.666

4.  Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone.

Authors:  J W Boersma
Journal:  Scand J Rheumatol       Date:  1976       Impact factor: 3.641

5.  Identification of adverse reactions to new drugs. I: What have been the important adverse reactions since thalidomide?

Authors:  G R Venning
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-15

6.  Correlation between ossification and inflammation using a rat experimental model.

Authors:  A Lussier; R de Medicis
Journal:  J Rheumatol Suppl       Date:  1983-12

Review 7.  Non-steroidal anti-inflammatory drugs. Current status and rational therapeutic use.

Authors:  F D Hart; E C Huskisson
Journal:  Drugs       Date:  1984-03       Impact factor: 9.546
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.